The data from our current study showed that the inclusion of myeloid lineage-associated markers, such as CD13, CD64, CD36, CD105, CD71, and CD33, in the gating strategy can increase the discriminatory power for distinguishing between AML blasts and normal HPCs that are committed toward different myeloid lineages. The gene discussed is CD36; the disease is acute myeloid leukemia.